A clinical-stage biotechnology company developing biologics to enhance regulatory T cell (Treg) function, Coya Therapeutics, has announced that MSCI has included its shares in the MSCI USA Micro Cap Index as of the market close on May 31, 2024. The MSCI USA Micro Cap Index measures the performance of the micro cap segment of the U.S. equity market, consisting of over 1,100 constituents with an average market cap of $122 million as of April 30, 2024. Numerous microcap ETFs track this benchmark and may adjust their holdings in the coming weeks to reflect the changes effective May 31. “Being selected by MSCI underscores the strategic focus and execution of the Coya team in creating sustainable shareholder value,” stated Howard Berman, Ph.D., CEO of Coya. “We remain committed to developing and commercializing therapies for neurodegenerative diseases like Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer’s disease, and Parkinson’s disease, and we anticipate several milestones in 2024 that could further strengthen our position.”
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 45 years of expertise in research, data, and technology, MSCI enables better investment decisions by helping clients understand and analyze key drivers of risk and return, thereby building more effective portfolios. MSCI’s research-enhanced solutions provide insights and transparency across the investment process. For more information, visit www.msci.com.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company developing proprietary treatments focusing on the biology and therapeutic potential of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs are implicated in numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, leading to sustained inflammation and oxidative stress, disrupting immune system homeostasis.
Coya’s investigational product pipeline leverages various therapeutic modalities to restore the anti-inflammatory and immunomodulatory functions of Tregs. The therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
COYA 302, the company’s lead investigational product or “Pipeline in a Product,” is a proprietary combination of COYA 301 (Coya’s proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration. This combination, with its unique dual mechanism of action, is being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s disease, and Alzheimer’s disease. The multi-targeted approach aims to increase the number and anti-inflammatory function of Tregs while reducing the activation of microglia and secretion of pro-inflammatory mediators. This synergistic mechanism may re-establish immune balance and reduce inflammation in a sustained and durable manner, which might not be achieved by either low-dose IL-2 or CTLA4-Ig alone.
